coxsackieviru
infect
found
account
increas
proport
case
hand
foot
mouth
diseas
hfmd
recent
epidemiolog
studi
singl
strand
nonenvelop
rna
viru
infect
caus
promin
health
threat
preschool
children
take
approach
revers
genet
establish
singleround
infect
system
pseudoviru
produc
sequenti
transfect
capsid
express
plasmid
replicon
rna
bear
firefli
luciferas
report
pseudoviru
system
use
quantifi
neutral
antibodi
ntab
level
human
serum
sampl
show
superior
specif
sensit
compar
tradit
cytopath
effect
cpe
assay
furthermor
compar
seropreval
ntab
preschool
children
healthi
adult
found
preschool
children
ntab
posit
suggest
children
naiv
infect
much
higher
posit
rate
adult
indic
adult
experienc
infect
childhood
rapid
quantit
assay
greatli
facilit
evalu
level
ntab
popul
help
advanc
vaccin
develop
coxsackieviru
member
coxsacki
b
virus
belong
genu
enteroviru
within
famili
picornavirida
import
pathogen
caus
asept
mening
myocard
acut
pancreat
sever
case
asept
mening
report
china
tao
et
al
tseng
et
al
wong
et
al
hand
foot
mouth
diseas
hfmd
case
also
notic
nation
notifi
diseas
surveil
system
nndss
hfmd
howev
still
effect
vaccin
antivir
drug
avail
neutral
antibodi
ntab
elicit
viral
infect
vaccin
convey
humor
protect
popul
essenti
viral
defens
thu
quantif
ntab
would
import
criterion
vaccin
evalu
well
assess
group
protect
human
popul
vaccin
tradit
neutral
assay
base
inhibit
cytopath
effect
cpe
virus
caus
cpe
effect
suscept
cell
line
vitro
includ
enteroviru
chang
et
al
coxsackieviru
well
howev
cpe
method
usual
take
day
inocul
let
plaqu
develop
laborintens
modifi
enzymelink
immunosorb
spot
assay
significantli
reduc
durat
time
still
shortcom
biosafeti
concern
rais
live
virus
limit
sensit
semi
quantit
result
due
poor
linear
huang
et
al
yang
et
al
howev
pseudoviru
base
neutral
assay
distinct
advantag
singleround
infect
ensur
superior
biosafeti
luciferas
report
enabl
sensit
quantif
bentley
et
al
pseudoviru
base
neutral
assay
wide
use
measur
neutral
antibodi
envelop
virus
human
immunodefici
viru
hiv
montefiori
influenza
viru
tsai
et
al
sever
acut
respiratori
syndrom
coronaviru
sarscov
li
et
al
sui
et
al
pseudovirus
envelop
virus
util
optim
lentiviru
retroviru
pseudotyp
system
common
pseudotyp
system
nonenvelop
virus
applic
revers
genet
picornaviru
enabl
us
get
full
length
infecti
viral
clone
pseudovirus
made
success
transencapsid
polio
viru
jia
et
al
jin
et
al
therebi
pseudoviru
base
neutral
assay
success
develop
wu
et
al
jin
et
al
howev
effici
pseudotyp
system
current
assay
detect
neutral
antibodi
cpe
base
assay
newli
report
elisa
assay
yang
et
al
work
first
establish
robust
pseudotyp
system
develop
neutral
assay
base
system
verifi
suitabl
measur
neutral
antibodi
human
serum
sampl
clinic
research
besid
use
assay
perform
small
scale
investig
seropreval
chines
popul
evalu
potenti
threat
caus
current
hfmd
diseas
control
human
embryon
kidney
cell
hek
human
rhabdomyosarcoma
porter
et
al
antipolio
viru
serum
standard
antisera
polio
viru
type
sabin
goat
serum
nt
titer
gift
institut
medic
biolog
chines
academi
medic
scienc
mous
serum
rais
immun
inactiv
viru
isol
patient
fuyang
citi
hfmd
epidem
china
genbank
access
subtyp
mous
anticoxsackieviru
serum
rais
immun
inactiv
strain
isol
threeyearold
patient
diagnos
herpangina
pizhou
citi
china
mous
antihepat
viru
hav
rais
immun
hav
vaccin
produc
sinovac
biotech
co
ltd
serum
sampl
collect
preschool
children
month
two
year
old
enrol
phase
iii
clinic
trial
inactiv
vaccin
clinicaltrialsgov
identifi
written
inform
consent
obtain
parent
guardian
subject
independ
ethic
committe
approv
obtain
ethic
committe
jiangsu
provinci
center
diseas
prevent
control
serum
sampl
collect
healthi
adult
year
old
hepat
viru
vaccin
cohort
approv
china
food
drug
administr
clinic
research
document
ethic
committe
jiangsu
provinci
center
diseas
prevent
control
written
inform
consent
particip
obtain
singl
round
infect
system
subgenom
replicon
replicon
construct
replac
capsid
code
region
firefli
luciferas
report
gene
infecti
viral
cdna
clone
kindli
provid
dr
jeffrey
bergelson
pan
et
al
proteas
cleavag
site
aittl
insert
luciferas
gene
replicon
linear
mlui
g
phenolchloroform
extract
dna
use
templat
replicon
rna
synthesi
ribomax
larg
scale
rna
product
kit
promega
follow
manufactur
instruct
transcrib
rna
purifi
isopropanol
precipit
use
transfect
frozen
c
use
nanci
capsid
express
construct
express
capsid
gene
tran
egfp
gene
insert
upstream
nanci
capsid
gene
separ
proteas
self
cleavag
site
aittl
egfp
report
use
monitor
transfect
effici
express
level
structur
gene
prepar
nanci
luc
nanci
luc
produc
sequenti
transfect
capsid
express
plasmid
replicon
rna
cell
briefli
nanci
capsid
express
revers
transfect
cell
confluenc
jetprim
polyplu
h
post
capsid
transfect
replicon
rna
transfect
lipofectamin
tm
life
technolog
nanci
luc
pseudoviru
harvest
h
post
rna
transfect
round
freezethaw
cycl
pseudoviru
stabl
c
least
six
month
without
signific
infect
decreas
viral
rna
extract
l
pseudoviru
sampl
qiaamp
viral
rna
mini
kit
qiagen
cdna
synthes
primescript
rt
reagent
kit
takara
viral
titer
quantifi
measur
genom
copi
equival
qpcr
use
sybr
premix
ex
taq
ii
perfect
real
time
takara
primer
target
firefli
luciferas
report
gene
use
qpcr
quantif
qlucf
qlucr
equal
amount
nanci
wild
type
viru
pseudoviru
l
mix
load
discontinu
sucros
gradient
follow
ultracentrifug
rpm
min
c
beckman
rotor
l
fraction
sampl
total
fraction
subject
rtqpcr
copi
number
viral
genom
rna
fraction
subsequ
determin
rtqpcr
nanci
viru
quantifi
primer
locat
specif
primer
firefli
luciferas
report
gene
qlucf
qlucr
use
quantifi
nanci
luc
pseudoviru
pseudoviru
titer
determin
measur
cell
cultur
infect
dose
use
microtitr
assay
l
two
fold
seri
dilut
nanci
luc
ad
plate
duplic
l
hela
cell
suspens
per
well
ad
later
incub
c
h
cell
lyze
passiv
lysi
buffer
measur
luciferas
activ
follow
manufactur
instruct
promega
luciferas
activ
measur
rel
light
unit
rlu
determin
singl
round
infect
system
schemat
map
viral
rna
genom
replicon
capsid
express
singl
round
infect
system
capsid
express
use
express
structur
capsid
gene
tran
egfp
gene
insert
upstream
nanci
capsid
gene
viral
genom
delet
egfp
separ
self
cleavag
site
aittl
structur
gene
replicon
produc
replac
capsid
code
region
firefli
luciferas
report
gene
full
length
genom
promot
place
end
transcript
vitro
b
c
rel
infect
nanci
wild
type
viru
hela
rd
vero
cell
b
immunostain
nanci
strain
wild
type
viru
infect
cell
cell
confluenc
plate
infect
nanci
viru
stain
mous
serum
h
post
infect
c
infect
ratio
quantifi
columbu
tm
perkinelm
rel
infect
nanci
luc
viru
hela
rd
vero
cell
cell
infect
l
nanci
luc
viru
copi
luciferas
activ
measur
h
post
infect
cell
rlu
time
background
consid
posit
pseudoviru
infect
background
control
cell
without
pseudoviru
infect
immunostain
infect
purif
nanci
recombin
protein
cdna
code
full
length
nanci
pro
precursor
clone
transform
cell
induc
iptg
c
h
lb
kan
recombin
protein
purifi
ninta
agaros
bead
qiagen
purifi
protein
concentr
aliquot
store
c
protein
emulsifi
equal
volum
complet
freund
adjuv
first
immun
incomplet
freund
adjuv
booster
weeksold
balbc
mice
immun
weekli
interv
gmous
serum
collect
one
week
third
booster
cell
fix
permeabil
icecold
methanol
min
room
temperatur
h
post
nanci
infect
wash
pb
incub
mous
polyclon
antibodi
dilut
bsapb
h
c
time
wash
pb
cell
incub
donkey
antimous
igg
hl
secondari
antibodi
alexa
fluor
conjug
dilut
bsapb
h
c
time
wash
pb
antifad
reagent
ad
observ
fluoresc
microscop
nikon
fluoresc
imag
analyz
columbu
tm
perkinelm
sera
heattreat
c
min
inactiv
complement
twofold
serial
dilut
sera
made
l
dilut
serum
taken
incub
equal
volum
dilut
pseudoviru
c
h
plate
l
hela
cell
suspens
per
well
ad
well
incub
co
incub
incub
medium
supernat
discard
cell
lyze
passiv
lysi
buffer
promega
two
round
freezethaw
cycl
store
c
measur
luciferas
activ
measur
rel
light
unit
rlu
determin
accord
luciferas
assay
system
user
manual
berthold
inhibit
ratio
calcul
rlu
viru
incub
serum
rlu
background
rlu
viru
control
rlu
background
nonlinear
regress
curv
plot
transform
dilut
concentr
inhibit
ratio
graphpad
titer
neutral
antibodi
determin
reciproc
dilut
complet
pseudoviru
neutral
brief
twofold
serial
dilut
sera
mix
equal
volum
l
viru
work
solut
contain
tissu
cultur
infect
dose
strain
genbank
access
c
h
microtit
plate
l
vero
cell
per
well
ad
incub
c
day
sera
test
duplic
neutral
titer
determin
reciproc
highest
dilut
well
show
complet
inhibit
cpe
statist
analysi
result
obtain
least
duplic
report
mean
standard
deviat
sd
statist
analys
perform
graphpad
prism
softwar
packag
first
establish
singleround
report
viru
system
could
produc
pseudoviru
high
titer
robust
infect
similar
strategi
appli
base
experi
previous
establish
singl
round
infect
system
subgenom
replicon
plasmid
replicon
contain
untransl
region
utr
firefli
luciferas
luc
report
gene
nonstructur
protein
region
promot
sequenc
upstream
end
use
vitro
transcript
capsid
express
plasmid
design
egfp
nanci
capsid
express
contain
structur
gene
egfp
report
gene
control
cmv
promot
fig
proteas
cleavag
sequenc
aittl
genom
introduc
replicon
luciferas
gene
nonstructur
gene
egfp
nanci
capsid
express
egfp
gene
capsid
effici
proteas
cleavag
upon
viral
polyprotein
translat
two
site
requir
viral
protein
matur
pseudoviru
encapsid
singl
round
pseudoviru
produc
sequenti
transfect
capsid
express
plasmid
subgenom
rna
transcrib
replicon
vitro
see
section
produc
viru
design
nanci
luc
pseudovirus
infect
cell
lack
structur
gene
capsid
provid
produc
cell
tran
success
product
high
titer
pseudoviru
show
insert
sequenc
could
effici
recogn
viral
proteas
next
compar
nanci
luc
wildtyp
viru
respect
tropism
virion
structur
antigen
sensit
differ
cell
line
wild
type
nanci
strain
fig
ultracentrifug
analysi
nanci
luc
pseudovirus
migrat
wild
type
viru
discontinu
sucros
fig
show
pseudoviru
particl
sediment
coeffici
wild
type
virion
nanci
luc
infect
could
neutral
mous
serum
dosedepend
manner
fig
next
verifi
antiserum
mice
immun
inactiv
nanci
virus
could
specif
neutral
infect
nanci
luc
standard
antisera
polio
viru
goat
serum
mous
serum
mous
anticoxsackieviru
serum
mous
antihepat
viru
hav
could
neutral
either
nanci
luc
fig
nanci
wild
type
viru
data
shown
infect
vitro
taken
togeth
result
prove
singeround
nanci
luc
pseudoviru
system
could
use
surrog
wild
type
viru
pseudoviru
provid
excel
tool
studi
entri
process
basic
research
avoid
ambigu
might
caus
post
entri
event
also
clinic
applic
previou
neutral
result
show
good
prospect
util
nanci
luc
detect
neutral
antibodi
clinic
sera
signific
indic
vaccin
efficaci
next
explor
feasibl
develop
vitro
neutral
assay
base
pseudoviru
express
firefli
luciferas
time
cours
experi
done
find
optim
incub
time
post
nanci
luc
infect
show
rlu
rather
stabl
h
h
post
infect
significantli
decreas
h
post
infect
fig
linear
rel
light
unit
rlu
nanci
luc
input
show
genom
equival
analyz
result
shown
quantit
linear
correspond
luciferas
activ
amount
input
viru
broad
rang
fig
nanci
luc
also
determin
dose
pseudovirus
per
well
linear
correspond
use
follow
experi
reproduc
import
criterion
consid
lack
nation
antibodi
standard
use
mous
serum
collect
mice
immun
formalin
inactiv
viru
strain
quantifi
neutral
activ
nanci
luc
pseudoviru
duplic
plate
six
independ
test
pearson
correl
analysi
neutral
result
six
independ
test
show
high
degre
reproduc
r
mous
serum
fig
previous
measur
neutral
antibodi
titer
serum
sampl
collect
preschool
particip
b
fig
character
nanci
luc
pseudoviru
ultracentrifug
analysi
nanci
luc
pseudoviru
nanci
wild
type
viru
pseudoviru
mix
appli
sucros
gradient
ultracentrifug
rpm
min
c
beckman
rotor
copi
number
viral
genom
rna
fraction
subsequ
determin
quantit
rtpcr
wild
type
viru
quantifi
primer
locat
nanci
luc
pseudoviru
primer
locat
firefli
luciferas
report
gene
b
specif
neutral
nanci
luc
antisera
antisera
includ
mous
anticoxsackieviru
serum
mous
antihepat
viru
hav
mous
serum
goat
serum
standard
antisera
polio
viru
mous
anticoxsackieviru
serum
serial
dilut
incub
nanci
luc
c
h
prior
infect
hela
cell
plate
total
volum
l
quadrupl
luciferas
activ
measur
h
post
infect
month
two
year
old
phase
iii
clinic
trial
inactiv
vaccin
use
tradit
cpe
assay
appli
newli
establish
pseudoviru
assay
reanalyz
titer
sampl
compar
result
cpe
data
use
capsid
protein
prototyp
nanci
strain
encapsid
pseudoviru
although
sequenc
align
capsid
protein
reveal
sever
mutat
strain
compar
nanci
strain
fig
neutral
data
use
assay
highli
consist
obviou
diverg
antigen
nanci
strain
observ
antibodi
standard
refer
known
concentr
unit
could
determin
antibodi
concentr
unit
instead
use
reciproc
dilut
complet
pseudoviru
neutral
tradit
cpe
assay
neutral
titer
determin
reciproc
highest
dilut
well
show
complet
inhibit
cpe
sampl
titer
consid
posit
otherwis
neg
two
set
data
underw
statist
analysi
sampl
posit
pseudoviru
assay
compar
posit
cpe
assay
spearman
correl
analysi
show
good
correl
result
two
assay
spearman
r
p
fig
blandaltman
method
comparison
analysi
show
two
method
highli
consist
averag
logarithm
differ
quantit
result
two
method
standard
deviat
fig
next
use
pseudoviru
assay
measur
neutral
antibodi
titer
serum
sampl
collect
health
adult
year
old
serum
sampl
seroposit
infant
particip
whose
serum
sampl
collect
within
period
adult
particip
pick
seropreval
analysi
found
preschool
group
significantli
lower
posit
ratio
adult
geometr
mean
neutral
antibodi
titer
preschool
children
ci
adult
ci
although
unpair
test
analysi
show
differ
titer
two
group
statist
signific
geometr
mean
titer
slightli
higher
adult
group
fig
detail
seropreval
pattern
would
discov
popul
stratifi
specif
group
accord
age
gender
transencapsid
method
use
produc
pseudovirus
picornavirus
polioviru
replicon
abl
pseudotyp
picornavirus
capsid
protein
provid
tran
though
variabl
effici
among
virus
effici
transencapsid
polioviru
replicon
jia
et
al
porter
et
al
previou
work
found
could
pseudotyp
replicon
moder
effici
howev
fail
pseudotyp
fig
establish
singl
round
infect
system
high
titer
use
replicon
found
neither
could
pseudotyp
replicon
fig
differ
compat
among
picornavirus
suggest
might
encapsid
signal
either
replicon
rna
tran
provid
capsid
protein
common
determin
might
found
virus
classifi
categori
accord
pseudotyp
compat
work
also
develop
quantit
pseudoviru
luciferas
assay
detect
neutral
antibodi
clinic
serum
sampl
assay
proven
safe
fast
sensit
show
good
correl
tradit
cpe
base
assay
assay
would
greatli
facilit
vaccin
develop
evalu
well
seropreval
survey
besid
applic
assay
could
also
use
screen
anti
human
monoclon
antibodi
entri
inhibitor
would
potent
antivir
drug
infect
although
capsid
nanci
strain
test
work
subtyp
readi
pseudotyp
capsid
protein
cross
neutral
activ
antibodi
could
easi
analyz
broad
neutral
antibodi
therapeut
valu
could
thu
identifi
well
potenti
differ
antigen
could
analyz
would
contribut
vaccin
candid
select
increas
infect
case
report
hfmd
surveil
chang
hfmd
pathogen
spectrum
notic
success
develop
effect
inactiv
wholeviru
vaccin
infect
case
would
drop
significantli
futur
might
promin
enteroviru
replac
serolog
investig
neutral
antibodi
popul
would
allow
us
assess
protect
level
viral
infect
work
also
small
scale
serolog
survey
health
adult
compar
seropreval
preschool
children
adult
exist
neutral
antibodi
reflect
previou
infect
higher
posit
rate
neutral
antibodi
adult
indic
infect
childhood
despit
differ
geograph
sampl
serolog
pattern
investig
yantai
citi
china
tao
et
al
low
posit
rate
neutral
antibodi
infant
indic
infant
higher
risk
potenti
outbreak
also
mani
enterovirus
includ
report
higher
posit
rate
titer
neutral
antibodi
adult
low
posit
rate
infant
preschool
children
make
suscept
enterovirus
infect
ji
et
al
ang
et
al
found
cross
neutral
select
enterovirus
pv
hev
use
sera
collect
mice
immun
inactiv
virus
fig
moreov
previous
measur
neutral
antibodi
titer
serum
sampl
collect
preschool
children
found
statist
signific
correl
neutral
antibodi
titer
data
shown
observ
indic
also
cross
neutral
human
taken
togeth
propos
neutral
antibodi
measur
simultan
next
would
substitut
firefli
luciferas
report
replicon
renilla
luciferas
report
use
previous
develop
pseudoviru
express
firefli
luciferas
pseudoviru
express
renilla
luciferas
measur
neutral
antibodi
viru
well
duel
pseudoviru
express
luciferas
report
system
would
minim
cost
requir
clinic
serum
volum
practic
mani
enterovirus
found
associ
hfmd
previou
hfmd
surveil
multival
vaccin
may
need
effect
hfmd
control
assay
capac
evalu
neutral
antibodi
multipl
pathogen
simultan
would
prefer
futur
summari
establish
singl
round
infect
system
develop
vitro
assay
detect
neutral
antibodi
clinic
serum
sampl
superior
surrog
assay
use
wild
type
virus
includ
tradit
cpe
assay
enzymelink
immunosorb
spot
assay
also
analyz
differ
seropreval
two
repres
popul
group
found
preschool
children
naiv
although
serum
sampl
divers
geograph
area
differ
age
need
get
detail
view
seropreval
work
provid
evid
might
impos
potenti
public
health
threat
effort
need
infect
control
